Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBD1016 in chronic hepatitis B
2023-503880-40-00Phase 2Completed
- Sponsor
- Suzhou Ribo Life Science Co., Ltd.
- Start
- May 2023
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing RBD1016 with Placebo (2 arms). Primary endpoints: Safety and Maximum HBsAg decline. Started May 2023; status: completed.
02
Drugs
RBD1016
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2023-503880-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503880-40-00.